AMO Pharma in Collaboration with Population Health Research Institute (PHRI) and Venca Research Inc. Announces FDA Advice on Potential Phase 3 Development Path for AMO-02 in Treatment of Arrhythmogenic Cardiomyopathy (ACM)
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference